================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
--------------
FORM 8-K
--------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): AUGUST 9, 2007
PROTEO, INC.
(Exact name of registrant as specified in its charter)
NEVADA 000-32849 88-0292249
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
2102 BUSINESS CENTER DRIVE, IRVINE, CALIFORNIA 92612
(Address of Principal Executive Offices)
Registrant's telephone number, including area code: (949) 253-4616
NOT APPLICABLE
(Former name or former address, if changed since last report)
--------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2 below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425).
|_| Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
-------------------------------------------
Proteo, Inc. announced today that it had entered into a license agreement
with Rhein Minapharm relating to the clinical development, production and
marketing of Elafin. Rhein Minapharm will exclusively market Elafin in Egypt,
Middle Eastern and African countries. Proteo will receive an upfront payment,
milestone-payments and royalties on net product sales. In addition, Minapharm
will take over the funding of clinical research activities for the designated
region. The agreement schedules the transfer of the biotechnological production
process of Elafin to Cairo.
A copy of the press release is attached to this Current Report as Exhibit
99.1.
9.01 FINANCIAL STATEMENTS AND EXHIBITS.
----------------------------------
(c) Exhibits. The following materials are filed as exhibits to this Current
report on Form 8-K:
Exhibit Number
--------------
99.1 Press release dated August 9, 2007
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PROTEO, INC.
Date: August 9, 2007 By: /s/ BIRGE BARGMANN
--------------------------------
Birge Bargmann
Chief Executive Officer